AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11759784 — intervention group
Group type: COMPARATOR
Intervention: Minimum interventions (MI)
Number of subjects: 0
Study 9010421 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Number of subjects: 8
Study 8328732 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 200 micrograms, four times a day for 12 weeks
Number of subjects: 638
Study 8328732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 3530858 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Acarbose with 100 g sucrose load
Number of subjects: 9
Study 3530858 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 100 g sucrose load
Number of subjects: 9
Study 30328494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (10 IU in 500 ml saline at 120 ml/h)
Number of subjects: 0
Study 30328494 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 0
Study 29894461 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐shaped minimal facelift incision (FLI)
Number of subjects: 46
Study 29894461 — intervention group
Group type: COMPARATOR
Intervention: Modified Blair incision (MBI)
Number of subjects: 46
Study 27391484 — intervention group
Group type: COMPARATOR
Intervention: High GI (GI ≥65) with high %carb (58 % kcal) (reference diet)
Number of subjects: 163
Study 27391484 — intervention group
Group type: COMPARATOR
Intervention: Low GI (≤45) with low %carb (40 % kcal)
Number of subjects: 163
Study 27391484 — intervention group
Group type: COMPARATOR
Intervention: Low GI with high %carb
Number of subjects: 163
Study 27391484 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing GI
Number of subjects: 163
Study 27391484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C and β2M
Number of subjects: 163
Study 24449626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 836
Study 24449626 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (TFA)
Number of subjects: 836
Study 22928433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy/compression device (group 1)
Number of subjects: 0
Study 22928433 — intervention group
Group type: COMPARATOR
Intervention: Standardized ice pack (group 2)
Number of subjects: 0
Study 19652108 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir drink
Number of subjects: 125
Study 19652108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (heat-killed matching placebo)
Number of subjects: 125
Study 17473774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (3.6 g.kg(‐1); HP)
Number of subjects: 5
Study 17473774 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.8 g.kg(‐1); LP)
Number of subjects: 5
Study 17473774 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (1.8 g.kg(‐1); MP)
Number of subjects: 5
Study 15051932 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (6.0 g/day)
Number of subjects: 50
Study 15051932 — intervention group
Group type: COMPARATOR
Intervention: Non-AST-120 (control)
Number of subjects: 50
Study 15051932 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study 11576048 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg x kg(‐1) x min(‐1)) combined with propofol (target plasma concentration of 1.5 microg x ml(‐1))
Number of subjects: 16
Study 11576048 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.8 %, 1.5 MAC)
Number of subjects: 16
Study 8135569 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (Elevit Pronatal)
Number of subjects: 3713
Study 8135569 — intervention group
Group type: COMPARATOR
Intervention: Trace elements
Number of subjects: 3713
Study 2597519 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 11
Study 2597519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 4458770 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0
Study 4458770 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 0
Study 4458770 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 4458770 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 31560223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA)
Number of subjects: 31
Study 31560223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA) + Frequency Modulated (FM) system
Number of subjects: 31
Study 31560223 — intervention group
Group type: COMPARATOR
Intervention: Normal Hearing (NH)
Number of subjects: 31
Study 30862584 — intervention group
Group type: EXPERIMENTAL
Intervention: New decision tree model for prognosis prediction
Number of subjects: 507
Study 30862584 — intervention group
Group type: COMPARATOR
Intervention: Tokuhashi score
Number of subjects: 507
Study 30862584 — intervention group
Group type: COMPARATOR
Intervention: Tomita score
Number of subjects: 507
Study 28081288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm; GS/group short)
Number of subjects: 101
Study 28081288 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11-15 mm; GG/group graft)
Number of subjects: 101
Study 25884448 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of neo‐adjuvant oxaliplatin‐based chemotherapy followed by surgery (arm B)
Number of subjects: 0
Study 25884448 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (standard treatment, arm A)
Number of subjects: 0
Study 23228215 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (130/0.4)
Number of subjects: 24
Study 23228215 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 24
Study 21762787 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 0
Study 21762787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 21762787 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 21762787 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study 19348303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stents
Number of subjects: 108
Study 16689620 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical cross-trainer submaximal test
Number of subjects: 54
Study 16689620 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted VO2max
Number of subjects: 54
Study 16689620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of prediction equation
Number of subjects: 54
Study 15236892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy
Number of subjects: 0
Study 15236892 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children with normal ENT examination)
Number of subjects: 0
Study 11099757 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise
Number of subjects: 0
Study 11099757 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise after five preexposures to the CS
Number of subjects: 0
Study 11099757 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS) - pure tone with unconditioned stimulus (US) - loud white noise after two preexposures to the CS
Number of subjects: 0
Study 11099757 — intervention group
Group type: COMPARATOR
Intervention: Control group with non-contingent CS and US presentation
Number of subjects: 0
Study 9448645 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation (TCS) of affected hemisphere (AH)
Number of subjects: 18
Study 9448645 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation (TCS) of unaffected hemisphere (UH)
Number of subjects: 18
Study 9448645 — intervention group
Group type: COMPARATOR
Intervention: Focal transcranial magnetic stimulation (TCS)
Number of subjects: 18
Study 9448645 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Number of subjects: 18
Study 8173018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 53
Study 8173018 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 53
Study 3169371 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg standard release disopyramide given three times daily
Number of subjects: 20
Study 3169371 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg sustained release disopyramide given twice daily
Number of subjects: 20
Study 3169371 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal ventricular function)
Number of subjects: 20
Study 3169371 — intervention group
Group type: COMPARATOR
Intervention: Control group (abnormal ventricular function)
Number of subjects: 20
Study 29445831 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (MIN)
Number of subjects: 1086
Study 29445831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (INT)
Number of subjects: 1086
Study 29445831 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized group (SPE)
Number of subjects: 1086
Study 29445831 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 1086
Study 29445831 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 1086
Study 27110697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab (10 mg/kg intravenously every 4 weeks through week 24)
Number of subjects: 25
Study 27110697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 patients)
Number of subjects: 25
Study 26450545 — intervention group
Group type: EXPERIMENTAL
Intervention: Small financial incentives (maximum $5.00 per week)
Number of subjects: 22
Study 26450545 — intervention group
Group type: COMPARATOR
Intervention: Non-incentive condition
Number of subjects: 22
Study 22795712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheterization strategy
Number of subjects: 345
Study 22795712 — intervention group
Group type: COMPARATOR
Intervention: Delayed catheterization strategy
Number of subjects: 345
Study 22795712 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IRF
Number of subjects: 345
Study 22795712 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed strategy in patients with IRF
Number of subjects: 345
Study 21565321 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 63
Study 21565321 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 19064574 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented diet (30 g/d)
Number of subjects: 161
Study 19064574 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented, low-fat diet
Number of subjects: 161
Study 19064574 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 161
Study 19064574 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<20% total energy)
Number of subjects: 161
Study 19064574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 161
Study 17073955 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 36
Study 17073955 — intervention group
Group type: COMPARATOR
Intervention: PMEA-coated CPB circuits
Number of subjects: 36
Study 14520146 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (10 mg/kg for patients <12 years; 600 mg for patients ≥12 years, intravenous/oral, 2-3 times daily)
Number of subjects: 958
Study 14520146 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 958
Study 10901647 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed technique
Number of subjects: 11
Study 10901647 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed technique
Number of subjects: 11
Study 9100721 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self‐Determination Act (PSDA)
Number of subjects: 9105
Study 9100721 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 9105
Study 9100721 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directives (ADs)
Number of subjects: 9105
Study 9100721 — intervention group
Group type: COMPARATOR
Intervention: No advance directive (AD)
Number of subjects: 9105
Study 7967990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inactivated whole-cell/recombinant-B-subunit cholera vaccine (WC/rBS)
Number of subjects: 1563
Study 7967990 — intervention group
Group type: COMPARATOR
Intervention: Escherichia coli K12 placebo
Number of subjects: 1563
Study 3304929 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg at night
Number of subjects: 50
Study 3304929 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night + 200 mg ofloxacin twice daily
Number of subjects: 50
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake (median (IQR) = 586 (459, 859) IU/d in early pregnancy)
Number of subjects: 187
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake (median (IQR) = 689 (544, 974) IU/d in late pregnancy)
Number of subjects: 187
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,25(OH)2D concentrations
Number of subjects: 187
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin D status in early pregnancy
Number of subjects: 187
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin D status in late pregnancy
Number of subjects: 187
Study 31732740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord serum 25(OH)D concentrations
Number of subjects: 187
Study 29912623 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 102
Study 27208667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (nutrition education and environmental dietary modification)
Number of subjects: 541
Study 27208667 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 541
Study 27208667 — intervention group
Group type: COMPARATOR
Intervention: Environmental dietary modification intervention
Number of subjects: 541
Study 27208667 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 541
Study 24615309 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw milk
Number of subjects: 16
Study 24615309 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized milk
Number of subjects: 16
Study 24615309 — intervention group
Group type: COMPARATOR
Intervention: Soy milk
Number of subjects: 16
Study 21797979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Number of subjects: 3
Study 21797979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue brushing
Number of subjects: 3
Study 21797979 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing only
Number of subjects: 3
Study 20683089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelimination games
Number of subjects: 29
Study 20683089 — intervention group
Group type: COMPARATOR
Intervention: Elimination games
Number of subjects: 29
Study 20683089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both game sessions
Number of subjects: 29
Study 20683089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both game types
Number of subjects: 29
Study 18650827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 or 100 mg) nightly for 36 weeks
Number of subjects: 76
Study 16647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibernating myocardium and/or inhomogeneity of sympathetic innervation identified by positron emission tomography imaging
Number of subjects: 0
Study 16647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cardiac positron emission tomography
Number of subjects: 0
Study 16647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up every three months
Number of subjects: 0
Study 16647885 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate device discharge in patients with an implantable cardiac defibrillator
Number of subjects: 0
Study 14744352 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (N = 26)
Number of subjects: 48
Study 14744352 — intervention group
Group type: COMPARATOR
Intervention: Nonstented group (N = 22)
Number of subjects: 48
Study 14744352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 10815785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 132
Study 10815785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 132
Study 8625230 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM (cisplatin 60 mg/m2 i.v. on Days 1 and 29; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Number of subjects: 102
Study 8625230 — intervention group
Group type: COMPARATOR
Intervention: FAM (5‐fluorouracil 600 mg/m2 i.v. on Days 1, 8, 29, 36; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Number of subjects: 102
Study 1483854 — intervention group
Group type: EXPERIMENTAL
Intervention: CBDCA + BCNU + VP‐16
Number of subjects: 84
Study 1483854 — intervention group
Group type: EXPERIMENTAL
Intervention: CBDCA + BCNU
Number of subjects: 84
Study 1483854 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP + VP‐16
Number of subjects: 84
Study 1483854 — intervention group
Group type: COMPARATOR
Intervention: BCNU alone
Number of subjects: 84
Study 3158783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 20
Study 3158783 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 20
Study 3158783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 30196973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 1119
Study 30196973 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 1119
Study 26799540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5mg
Number of subjects: 300
Study 26799540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 25171742 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme for parents of children with AD
Number of subjects: 274
Study 23631796 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (646 mg in 4 ml) administered every 12 hours for 6 months
Number of subjects: 153
Study 23631796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 20801246 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck manipulation
Number of subjects: 182
Study 20801246 — intervention group
Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 182
Study 19169063 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Care
Number of subjects: 25
Study 15837905 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises (treatment group, n = 43)
Number of subjects: 116
Study 15837905 — intervention group
Group type: COMPARATOR
Intervention: No exercises (no-treatment group, n = 73)
Number of subjects: 116
Study 15837905 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises (treatment group)
Number of subjects: 116
Study 15837905 — intervention group
Group type: COMPARATOR
Intervention: No exercises (no-treatment group)
Number of subjects: 116
Study 12898489 — intervention group
Group type: EXPERIMENTAL
Intervention: ED group (received azithromycin from the ED)
Number of subjects: 74
Study 12898489 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy group (prescription for azithromycin to be filled at a local pharmacy)
Number of subjects: 74
Study 12898489 — intervention group
Group type: EXPERIMENTAL
Intervention: ED group
Number of subjects: 74
Study 12898489 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy group
Number of subjects: 74
Study 12898489 — intervention group
Group type: EXPERIMENTAL
Intervention: ED group and Pharmacy group
Number of subjects: 74
Study 10566643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soy supplementation (60 g, 45 mg isoflavones)
Number of subjects: 84
Study 8739813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg tablet, three times daily for 3 months (TID group)
Number of subjects: 7274
Study 8739813 — intervention group
Group type: COMPARATOR
Intervention: Slow release nicardipine, 50 mg twice daily for 3 months (BID group)
Number of subjects: 7274
Study 2065042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking and jogging)
Number of subjects: 50
Study 2065042 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic strength exercise (circuit Nautilus training)
Number of subjects: 50
Study 2065042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (aerobic and nonaerobic)
Number of subjects: 50
Study 2065042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study 7014726 — intervention group
Group type: EXPERIMENTAL
Intervention: new chromone compound
Number of subjects: 28
Study 7014726 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 28
Study 30871947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacritose (50g)
Number of subjects: 41
Study 30871947 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50g)
Number of subjects: 41
Study 30871947 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (50g)
Number of subjects: 41
Study 27616436 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing clinic correspondence and endoscopy reports to patients
Number of subjects: 70
Study 27616436 — intervention group
Group type: COMPARATOR
Intervention: No correspondence provided (Control)
Number of subjects: 70
Study 26871534 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative hypnotic suggestions (based on the Pain Catastrophizing Scale)
Number of subjects: 44
Study 26871534 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive hypnotic suggestions (coping-oriented reversion of the Pain Catastrophizing Scale)
Number of subjects: 44
Study 26871534 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral hypnotic suggestions (neutral sentence)
Number of subjects: 44